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Abstract: Atrial fibrillation the most common cardiac arrhythmia. Its incidence rises steadily with
each decade, becoming a real “epidemic phenomenon”. Cardioversion is defined as a rhythm control
strategy which, if successful, restores normal sinus rhythm. This, whether obtained with synchronized
shock or with drugs, involves a periprocedural risk of stroke and systemic embolism which is reduced
by adequate anticoagulant therapy in the weeks before or by the exclusion of left atrial thrombi.
Direct oral anticoagulants are safe, manageable, and provide rapid onset of oral anticoagulation;
they are an important alternative to heparin/warfarin from all points of view, with a considerable
reduction in bleedings and increase in the safety and quality of life of patients.
Keywords: direct oral anticoagulants (DOACs); atrial fibrillation (AF); electrical cardioversion (EC)
1. Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide. It is nowadays a real
“epidemic phenomenon” considering an incidence of approximately 25% in patients aged >40 years
with high prevalence in elderly patients [1–6]. The worldwide prevalence of atrial fibrillation in the
near future will necessitate mandatory, safe, and effective management [5,6].
Cardioversion is defined as a rhythm-control strategy that, if successful, restores normal sinus
rhythm. There are two types of cardioversion: pharmacological (the preferred strategy in patients
presenting with recent-onset AF; within 48 h) and electrical (the preferred strategy when AF is
prolonged). Cardioversion is very important in the management of AF [7,8]; indeed, delays in
cardioversion promote atrial remodeling and difficult sinus rhythm restoration, increasing the likelihood
of postcardioversion AF recurrence and adding further thromboembolic risk [8–10]. In fact, sinus
rhythm restoration, either obtained with electrical cardioversion or with drugs, carries a periprocedural
risk of stroke and systemic embolism which is decreased by adequate anticoagulation in the weeks before
cardioversion or excluding left atrial thrombi before the procedure [1,9–14] (see Figure 1). For these
reasons, prophylactic anticoagulation represents a cornerstone of peri-cardioversion management in
patients with AF [1–12], even if, in patients with datable AF (less than 48 h), it is usual to perform
cardioversion without transesophageal echocardiogram (TEE) or antecedent oral anticoagulant therapy
(OAT) [12–14]. Randomized controlled trials (RCTs) comparing direct oral anticoagulant (DOAC)
therapies in patients with AF duration of <48 h are not available. The same applies to patients
with hemodynamic instability and AF that can undergo cardioversion immediately [12]. Long-term
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OAT after cardioversion should be based on the long-term risk of stroke using the CHA2DS2-VASc
(Congestive Heart failure, hypertension, Age ≥75 – doubled-, Diabetes, Stroke –doubled-, Vascular
disease, Age 65–74, and Sex female) risk score. If the duration of AF lasted more than 48 h, or its
onset is not evaluable, the periprocedural risk of thromboembolism can be as high as 5–7% without
anticoagulant therapy [12,14]. In this clinical situation, current guidelines recommend therapeutic
anticoagulation for at least 3 weeks before and at least 4 weeks after cardioversion [12–14] (see Figure 1).
It is important to underline that the highest risk of thromboembolism is within the first 7 days after
cardioversion (>80% of events) with the greatest risk within the first 72 h [15]. An embolic event after
cardioversion can be due both to the fact of left atrial thrombi migration or to the subsequent formation
and migration of de novo thrombi caused by postcardioversion atrial stunning [8]. The single biggest
risk factor for thrombus formation is inadequate anticoagulation [1,12–16]. In the current European
Society of Cardiology (ESC) Guidelines for the management of AF [12], the recommendation for
anticoagulation with warfarin before cardioversion is in first class for a time ≥3 weeks and must be
continued for ≥4 weeks after the procedure, based on pathophysiological and observational data [12].
Compared to vitamin K antagonist (VKA) therapy, the use of DOACs offers potential advantages in the
setting of cardioversion, although their use is recommended in Class IIa in the last ESC Guidelines [12].
These advantages include a faster onset of therapeutic anticoagulant effects, avoidance of heparin
bridging, and improved quality of life avoiding the mandatory blood sample to control international
normalized ratio (INR) range when vitamin K antagonist are used [14].
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Figure 1. Suggested flow chart for atrial fibrillation (AF) cardioversion on the basis of the
current European Society of Cardiology (ESC) Guidelines. Transesophageal echocardiogram (TEE),
anticoagulant therapy (OAT), left atrial appendage (LAA), sinus rhythm (SR).
The use of DOACs in this setting of patients is based on subgroup analyses of Randomized
Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY) for dabigatran [16], from Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention
of Stroke and Embolism Trial in Atrial Fibrillation trial (ROCKET AF) for rivaroxaban [17], and
from Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
trial (ARISTOTLE) for apixaban [18]. Moreover, recent important studies on DOACs suggest new
possibilities in cardioversion and deserve to be examined [13,14,19]. These important pieces of evidence
have been considered by the American Heart Association (AHA), American College of Cardiology
(ACC), and the Heart Rhythm Society (HRS) in the recent 2019 Focused Update of the 2014 AF
Guideline [13]. Thus, the aim of this review was to summarize the state-of-the-art methods regarding
the use of DOACs in relation to cardioversion.
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2. DOACs for Cardioversion in Atrial Fibrillation
From a purely academic and explanatory point of view, we consider four different scenarios
regarding cardioversion, which we examine point by point:
• Cardioversion of AF patient treated for >3 weeks with DOACs: we consider the subgroup analyses
from RE-LY (dabigatran), ROCKET-AF (rivaroxaban), and ARISTOTLE (apixaban), including
important news from the “eXplore the efficacy and safety of once-daily oral riVaroxaban for the
prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for
cardioversion trial” (X-VeRT study) [20].
• Cardioversion of AF of >48 h in a patient not on DOACs: we consider the X-VeRT study [20] and
“Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fi brillation
trial” (ENSURE AF) [21].
• Cardioversion of recent onset AF in an anticoagulation-naive patient: in this scenario, the results of
the “Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnticoagulaTion
in subjects with atrial fibrillation trial” (EMANATE trial) are very important [22].
• Patients with evidence of left atrial appendage (LAA) thrombus: we consider the few studies
available in the literature on this scenario.
2.1. Cardioversion of AF Patient Treated for >3 Weeks with DOACs
The initial data on the use of DOACs in a clinical setting for cardioversion came from the
post-hoc subgroup analysis of randomized control trials (RCTs) RE-LY [16], ROCKET AF [17], and
ARISTOTLE [18].
In the RE-LY trial [16,23,24], from a total of 1983 cardioversions, patients received dabigatran
110 mg BID, dabigatran 150 mg BID, and warfarin. It was recommended that patients assigned to
dabigatran receive at least 3 weeks of therapy before cardioversion. Stroke and systemic embolism
rates at 30 days were 0.77 for dabigatran 110 mg BID, 0.60 for warfarin, 0.30 for dabigatran 150 mg
BID, without significant differences among the treatment groups (dabigatran 110 mg versus warfarin,
p = 0.71; dabigatran 150 mg versus warfarin, p = 0.40). Stroke and systemic embolism rates were
similar in patients undergoing TEE before cardioversion (25% of patients assigned to dabigatran and
13% of patients assigned to warfarin) and in patients not performing TEE. Major bleeding rates were
1.7% for dabigatran 110 mg group, 0.6% for dabigatran 150 mg, and 0.6% for warfarin (dabigatran
110 mg versus warfarin, p = 0.06; dabigatran 150 mg versus warfarin, p = 0.99).
The ROCKET AF post-hoc analysis [25] investigated patient outcomes with both cardioversion
and catheter ablation procedures; 143 patients underwent electrical cardioversion, 142 underwent
pharmacological cardioversion, and 79 underwent catheter ablation. The incidence of stroke or systemic
embolism (1.88% versus 1.86%) and death (1.88% versus 3.73%) were similar in the rivaroxaban-treated
and warfarin-treated groups. No data were available regarding the use of TEE pre-cardioversion.
Major bleeding rates were 18.75% in the rivaroxaban group and 13.04% in the warfarin group. It is
important to consider and remember that elective cardioversions were excluded by the enrolling
protocol in ROCKET AF, i.e., patients who underwent cardioversion or ablation due to the fact of
hemodynamic instability, progressive heart failure, or refractory symptoms despite optimal medical
therapy [25].
In the ARISTOTLE trial [18,26], we found 540 cardioversions, and 265 patients received apixaban
and 275 received warfarin. A TEE pre-procedural was performed in about 27% of cases. In the first
30 days after cardioversion, no patients experienced a thromboembolic event; one myocardial infarction
(MI) and one major bleeding (MB) event occurred in each group, with two deaths in each group.
In most cases, cardioversion occurred after months of treatment, with a mean time from enrolment to
cardioversion of 243 ± 231 days for patients assigned to warfarin and of 251 ± 248 days for patients
assigned to apixaban, far longer than the 3 weeks recommended by international guidelines [27].
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Subgroup analyses from RE-LY, ROCKET-AF, and ARISTOTLE underline that electric cardioversion
in patients treated with DOACs had a low and similar thromboembolic risk than patients treated with
warfarin. According to these data, cardioversion without TEE seems reasonably safe under regular
and continued DOAC intake.
2.2. Cardioversion of AF of >48 h in a Patient Not on DOACs Therapy
The X-VeRT, ENSURE-AF, and EMANATE studies [20–22] were evaluated in the context of
DOAC-naïve patients, respectively, with rivaroxaban (57% of patients), edoxaban (47%), and apixaban
(61%) (see Figure 2).
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The X-VeRT study [20] is the first prospective randomized trial of DOACs in patients with atrial
fibrillation undergoing elective cardioversion. Rivaroxaban was compared with dose adjusted VKA in
the prevention of cardiovascular events in 1504 patients wit non valvular atrial fibrillation (NVAF)
scheduled for early or delayed cardioversion at the discretion of the local cardiologist investigator.
In the early approach, oral anticoagulant therapy was given 1–5 days before cardioversion and, in the
rivaroxaban arm, a cardioversion was performed at least 4 h after the first dose. In the delayed
cardioversion approach, atients ere anticoagulated for a range of 3–8 weeks before the procedure.
Prophylaxis with rivaroxaban was considered adequate if the pill count as ≥80% in the three weeks
preceding the cardioversion. The procedure was g i e in 65% of patients treated with an early
strategy, whereas a TEE-guided cardioversion was performed in 10% of patients using a delayed
strategy, with no significant difference in the rate of TEE employment a ong the two treatment
groups. Primary efficacy endpoi ts were a composite of stroke and transient ischemic attack (TIA),
on- systemic embolism, MI, CV death, while rimary safety e dpoints were MB. The primary efficacy
endpoint occurred in 0.51% of patients in the rivaroxaban arm and 1.02% of patients in the VKAs arm
(risk ratio 0.50; 95% CI 0.15–1.73). Majour bleedin (MB) occurred in 0.6% of patients in the rivaroxaban
group and in 0.8 of patients in the VKAs group (risk ratio 0.76; 95% CI 0.21–2.67). Rivaroxaban was
associated with l w rates of adverse outcomes similar to those of VKAs even when data from the early
and delayed strategies were analyzed separately. A important difference was found amo g the two
strategies i terms of median ti e to cardioversion. This data were similar in the early strat g but
significantly shorter in the delayed str tegy using rivaroxaban versus warfarin (22 days rivaroxaban
arm versus 30 days in VKA arm). Only 36% of patients anticoagulated with VKA were cardioverted as
scheduled as the INR was not in range, in comparison with 77% in the rivar xaban arm. According
to dat from X-VeRT, rivaroxab n can b considered as an ffecti and safe alternative to VKAs in
patients with AF addressed to cardioversion, irrespective of the timing of the procedure. Moreover,
X-VeRT showed that ri aroxaban may overcome critical limitations of VKA treatment in the s tting of
cardioversion, including a significant r duction in time to cardioversion nd a considerabl reduction
of conomic expenditure.
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In the ENGAGE AF-TIMI 48 trial [28] few patients underwent electrical cardioversion and,
therefore, we have limited data about edoxaban in the setting of procedures. Further data
about anticoagulation with edoxaban in patients undergoing cardioversion are provided by the
ENSURE-AF [21] which is the largest prospective randomized clinical trial of anticoagulation for
cardioversion of patients with non-valvular atrial fibrillation. In this trial, 2199 patients scheduled
for cardioversion were randomized (1:1) to edoxaban or enoxaparin/warfarin. As in the X-VeRT
trial, patients were stratified in two different approaches. In the TEE-guided group, the TEE and
cardioversion had to be executed within 3 days of randomization and patients randomly addressed
to the edoxaban group had to begin treatment at least 2 h before electrical cardioversion. In the
non-TEE-guided group, electrical cardioversion was executed at a minimum of 21 days following the
start of anticoagulation. The primary endpoint (PE) was a composite of stroke, systemic embolic event
(SEE), MI, and cardiovascular (CV) mortality, while the primary safety endpoint was a composite of
major and non-major but clinically relevant bleeding (CRNM). The primary endpoint was similar
with edoxaban compared to enoxaparin/warfarin in patients undergoing electrical cardioversion of
NVAF (<1% edoxaban arm versus 1% enoxaparin/warfarin, odds ratio (OR) 0·46, 95% CI 0·12–1·43) and
was independent of TE or previous anticoagulant therapy. The composite of the PE was numerically
lower for edoxaban versus enoxaparin/warfarin and the main difference was due to the cardiovascular
mortality, (0.1% in the edoxaban group versus 0.5% in the enoxaparin–warfarin). The primary safety
endpoint occurred in 1.5% and 1.0% of patients in the edoxaban versus the enoxaparin/warfarin arm,
respectively, and the results were statistically non-significant. There were numerically more major
bleedings in the enoxaparin/warfarin arm, while more CRNM bleedings were found in the edoxaban arm.
The net clinical outcome (composite of stroke/systemic embolism/myocardial infarction/cardiovascular
death/major bleeding) was numerically lower in the edoxaban arm versus the enoxaparin/warfarin
arm, but the result was statistically non-significant. In contrast with the X-VeRT study, there was no
difference in time to delayed cardioversion among the two treatment groups. This probably means that
the ENSURE-AF trial compared edoxaban with the optimized standard care of enoxaparin, bridging
the pending therapeutic warfarin. The results suggest that edoxaban may be an effective and safe
alternative to enoxaparin/VKA strategy and may allow prompt cardioversion to be performed when
following a TEE-guided approach (edoxaban almost 2 h before ECV).
2.3. Cardioversion of Recent Onset AF, in an Anticoagulation-Naive Patient
In this very important scenario, a key role is represented by EMANATE study [22]; this was
the first study in anticoagulation-naive patients scheduled for cardioversion. All patients received
<48 h anticoagulation and 61% were not anticoagulated prior to randomization. One thousand and
thirty-eight patients underwent cardioversion, whereas 300 spontaneously restored sinus rhythm;
162 patients were not cardioverted; and in only 855 patients was imaging test (TEE or CT) performed. In
some patients randomized to apixaban, according to the investigator, before the cardioversion, a single
10 mg loading dose of apixaban could be administered to achieve exposure at 2 h similar to steady
state. Instead the maintenance dose was down titrated to 5 mg. Cardioversion could be performed 2 h
after administration of the loading dose; 342 of patients received a loading dose of apixaban. The result
of apixaban versus heparin/VKA group showed in EMANATE trial was: 0 versus 6 strokes (p = 0.0164),
3 versus 6 major bleeds, 2 versus 1 deaths, and no systemic embolic events in both groups. Among
342 patients receiving the loading dose of apixaban, there were 0 strokes, 1 major bleed, and 1 death.
Finally, imaging identified left atrial appendage thrombi in 61 patients; all continued anticoagulation.
Among those who underwent second imaging examination (37 ± 11 days after the initial imaging)
thrombi resolved in 52% versus 56% in the apixaban and heparin/VKA groups. The EMANATE
study supports the use of apixaban in patients with AF undergoing cardioversion. The novelty of
this trial was the exclusive enrolment of anticoagulant-naïve patients (62% not receiving, 38% < 48 h)
with recently detected AF (new onset or first diagnosed) with a focus on enrolling those amenable to
early cardioversion. Also unique to the study, if an immediate cardioversion was planned, there was
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administration of a loading dose (10 mg) of apixaban at least 2 h before cardioversion. For this reason,
potential participants were actively identified in hospital emergency departments which encouraged
but did not mandate imaging (TEE or CT).
2.4. Management of a Patient with Documented Left Atrial Appendage Thrombus
The left atrial appendage is the site with the highest blood stasis which causes thrombus formation
during atrial fibrillation [29]. In fact, about 90% of intracardiac thrombi in patients with cardioembolic
events originally develop in the LAA. In patients with evidence of LAA thrombus cardioversion should
not be performed. In patients with AF VKA, current guidelines recommend therapy for 3 weeks
after diagnosis of an LA/LAA thrombus and long-term therapy for those with a documented residual
thrombus [12,30]. Although relevant studies showing differences between DOAC and VKA (small data,
although very interesting and encouraging, can be derived from the EMANATE study) do not yet exist,
in the past few years, there some evidence has emerged supporting the use of DOACs for LA/LAA
thrombus resolution, even if the data are limited to case studies or small case series [31]. The X-TRA
study was the first prospective, multicenter study examining thrombus resolution with rivaroxaban
in VKA-naïve patients or patients receiving suboptimal or ineffective VKA therapy [31]. This study
showed that resolution or reduction of thrombus after rivaroxaban treatment was comparable to the
results obtained with VKA therapy according to prior retrospective observational case series and the
retrospective CLOT-AF registry [31]. The results suggest that rivaroxaban seems to be a potential
option for the treatment of TEE-detected LA/LAA thrombi in patients with AF [31]. Even dabigatran
has generated encouraging data regarding its use for LA/LAA thrombus resolution [32]. In a small
study with a total of 58 AF patients with LAA thrombus, Xiao et al. [32] demonstrated that dabigatran
was effective in the dissolution of LAA thrombus in patients with AF. Ongoing trial RE-LATED-AF will
make further clarifications about the use of DOACs in this complex and poorly studied scenario [33].
3. Conclusions
For several years, warfarin has been the primary oral anticoagulant used for patients with AF [34],
affirming its superiority over acetylsalicylic acid in reducing thromboembolic risk [1,11–13]. Since
2009 until 2013, the four DOAC registered RCTs have paved the way for a more optimal prevention
of thromboembolic risk in patient with AF, reducing hemorrhagic risk; in particular, all DOACs
significantly reduced the risk of intracranial hemorrhage (ICH), principally in more complex categories
of patients such as in the elderly, frail, and patients with comorbidities (Figure 2) [5,6,35].
Direct oral anticoagulants (DOACs) offer several potential advantages over warfarin therapy
in the setting of cardioversion, including removing the need for routine laboratory monitoring and
heparin bridging therapy (the latter of which is very important, especially in the case of surgical
interventions), as well as having predictable pharmacokinetic and security pharmacodynamic profiles.
Finally, DOACs demonstrated good predictable onset of anticoagulation (since 1 to maximum
4 h) compared with 48 to 72 h for warfarin and up to 5 to 7 days to reach steady state [36,37]. In a
very interesting random-effects meta-analysis performed by Brunetti et al. [38], a total of 8564 patients
undergoing both electrical and pharmacologic cardioversions for NVAF were included observing,
one more time, the effectiveness and safety of DOACs in patients undergoing NVAF.
Unfortunately, today, head-to-head studies do not exist and direct comparisons between DOACs
are not possible. Even though other studies concerning DOACs in the context of AF are ongoing (for
example, the RE-LATED AF-AFNET 7 trial [33]) and further real-life data are needed, DOACs therapy
is an effective and safe strategy in the context of atrial fibrillation patients scheduled for cardioversion.
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